CN104321073A - 包含骨桥蛋白及含钙和/或锶粒子的纳米粒子聚集体 - Google Patents

包含骨桥蛋白及含钙和/或锶粒子的纳米粒子聚集体 Download PDF

Info

Publication number
CN104321073A
CN104321073A CN201380025647.3A CN201380025647A CN104321073A CN 104321073 A CN104321073 A CN 104321073A CN 201380025647 A CN201380025647 A CN 201380025647A CN 104321073 A CN104321073 A CN 104321073A
Authority
CN
China
Prior art keywords
opn
particle
nanometer particle
calcium
nanoparticle aggregates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380025647.3A
Other languages
English (en)
Chinese (zh)
Inventor
亨里克·比克达尔
雅各布·奥尔森
乔纳斯·斯科夫高
塞巴斯蒂安·施拉弗尔
里科·路易斯·梅尔
本特·尼瓦德
邓肯·斯图尔特·萨瑟兰
彼得·朗堡·魏谢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
Original Assignee
Arla Foods AMBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods AMBA filed Critical Arla Foods AMBA
Publication of CN104321073A publication Critical patent/CN104321073A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A61K8/0275—Containing agglomerated particulates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380025647.3A 2012-03-28 2013-03-27 包含骨桥蛋白及含钙和/或锶粒子的纳米粒子聚集体 Pending CN104321073A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12161802 2012-03-28
EP12161802.9 2012-03-28
PCT/EP2013/056598 WO2013144247A1 (en) 2012-03-28 2013-03-27 Nanoparticle aggregates containing osteopontin and calcium- and/or strontium-containing particles

Publications (1)

Publication Number Publication Date
CN104321073A true CN104321073A (zh) 2015-01-28

Family

ID=48141914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380025647.3A Pending CN104321073A (zh) 2012-03-28 2013-03-27 包含骨桥蛋白及含钙和/或锶粒子的纳米粒子聚集体

Country Status (13)

Country Link
US (2) US20150044260A1 (https=)
EP (1) EP2830647A1 (https=)
JP (1) JP2015516949A (https=)
KR (1) KR20150004814A (https=)
CN (1) CN104321073A (https=)
AR (1) AR090569A1 (https=)
AU (1) AU2013241750A1 (https=)
CA (1) CA2868684A1 (https=)
CL (1) CL2014002583A1 (https=)
EA (1) EA201491691A1 (https=)
MX (1) MX2014011594A (https=)
NZ (1) NZ700295A (https=)
WO (1) WO2013144247A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111366733A (zh) * 2020-03-07 2020-07-03 浙江大学 骨桥蛋白作为靶分子在调节肠道菌群定植中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
US12109284B2 (en) 2016-11-08 2024-10-08 Dentherapy Ltd Compositions comprising fluoride and calcium and method for preparing them
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US20220183933A1 (en) * 2019-03-22 2022-06-16 The Board Of Regents Of The University Of Oklahoma Surface-modified doped titanium dioxide nanoparticles and uses
EP4129413A4 (en) * 2020-03-27 2024-04-24 NOF Corporation Composition for oral cavity
GB202010987D0 (en) 2020-07-16 2020-09-02 Dentherapy Ltd Oral care compositions and methods
GB202110114D0 (en) 2021-07-14 2021-08-25 Dentherapy Ltd Oral care compositions for use in treaatment
WO2023187028A1 (en) * 2022-03-31 2023-10-05 Nadavia Holding Aps Mouthwash composition comprising one or more strontium salt
WO2025008636A1 (en) 2023-07-06 2025-01-09 Dentherapy Ltd Oral care compositions for use in the treatment of dental health conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049741A2 (en) * 2000-01-07 2001-07-12 Arla Foods Amba A process for isolation of osteopontin from milk
CN1889922A (zh) * 2003-12-01 2007-01-03 阿尔拉食品公司 骨桥蛋白在牙用制剂中的用途
WO2009010071A1 (en) * 2007-07-16 2009-01-22 Aarhus Universitet Osteopontin nanoparticles system for drug delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507335A (en) 2000-10-05 2004-10-29 New Zealand Dairy Board Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP
EA200870058A1 (ru) * 2005-12-16 2008-12-30 Арла Фудс Амба Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран
AU2012222312B2 (en) 2011-03-03 2017-06-08 Arla Foods Amba Method for isolating osteopontin using feeds containing cmp or casein species

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049741A2 (en) * 2000-01-07 2001-07-12 Arla Foods Amba A process for isolation of osteopontin from milk
CN1889922A (zh) * 2003-12-01 2007-01-03 阿尔拉食品公司 骨桥蛋白在牙用制剂中的用途
WO2009010071A1 (en) * 2007-07-16 2009-01-22 Aarhus Universitet Osteopontin nanoparticles system for drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
T. JENSEN ET AL.: "Osteopontin functionalization of hydroxyapatite nanoparticles in a PDLLA matrix promotes bone formation", 《J BIOMED MATER RES PART A 》, 28 July 2011 (2011-07-28), pages 94 - 101 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111366733A (zh) * 2020-03-07 2020-07-03 浙江大学 骨桥蛋白作为靶分子在调节肠道菌群定植中的应用
CN111366733B (zh) * 2020-03-07 2022-02-08 浙江大学 骨桥蛋白作为靶分子在调节肠道菌群定植中的应用

Also Published As

Publication number Publication date
MX2014011594A (es) 2015-07-06
US20170065673A1 (en) 2017-03-09
EA201491691A1 (ru) 2015-04-30
WO2013144247A1 (en) 2013-10-03
JP2015516949A (ja) 2015-06-18
CA2868684A1 (en) 2013-10-03
AU2013241750A8 (en) 2014-10-23
US20150044260A1 (en) 2015-02-12
KR20150004814A (ko) 2015-01-13
AU2013241750A1 (en) 2014-10-09
EP2830647A1 (en) 2015-02-04
NZ700295A (en) 2016-07-29
AR090569A1 (es) 2014-11-19
CL2014002583A1 (es) 2015-06-12

Similar Documents

Publication Publication Date Title
CN104321073A (zh) 包含骨桥蛋白及含钙和/或锶粒子的纳米粒子聚集体
He et al. Polyzwitterion manipulates remineralization and antibiofilm functions against dental demineralization
Bapat et al. The use of nanoparticles as biomaterials in dentistry
JP7058344B2 (ja) 歯肉健康を促進するための口腔ケア組成物
JP7058343B2 (ja) 歯肉健康を促進するための口腔ケア組成物
JP7058341B2 (ja) 歯肉健康を促進するための口腔ケア組成物
JP7058342B2 (ja) 歯肉健康を促進するための口腔ケア組成物
RU2404738C2 (ru) Стабилизированные комплексы фосфата кальция
RU2673820C2 (ru) Стоматологический продукт для отбеливания зубов
Abdelnabi et al. Effect of different formulations and application methods of coral calcium on its remineralization ability on carious enamel
JP5973585B2 (ja) ラクトフェリン機能化表面を有する生体模倣ヒドロキシアパタイト粒子を含有するデンタルケア製品
Babayevska et al. Novel nanosystems to enhance biological activity of hydroxyapatite against dental caries
Lu et al. Applications of photothermally mediated nanohybrids for white spot lesions in orthodontics
AU2013294718B2 (en) Oral care and oral hygiene products having photocatalytic activity comprising inorganic particles superficially functionalised with TiO2 nanoparticles
Xu et al. VMT/ACP/Dextran composite nanosheets against dental caries through promoting mineralization of dentin tubules, pH buffering, and antibacterial
El-Gar et al. Potent antibacterial and antibiofilm activities of a synthetic remineralizing preparation of nano-hydroxyapatite against cariogenic Streptococcus mutans using an ex-vivo animal model
CN105287244A (zh) 蒙脱石功能性牙膏及其制备方法
Guo et al. Preparation of CMC/ACP/PHMB nanocomposites and preliminary study on their antibacterial and remineralization functions
Tabari et al. The Effect of Silicone Oil and Nano-hydroxyapatite/Chitosan Powder on Microhardness and Surface Structure of Primary Teeth Enamel After Iron Drop Consumption.
EP4248944A1 (en) Antiseptic composition containing 9-hydroxycalabaxanthone
Sulistyawati et al. Effectiveness of Nano-hydroxyapatite in Caries Prevention: Literature Review
JP2015224233A (ja) 歯牙清掃処置用組成物
EP3393598B1 (en) A composite for biofilm control
Lv et al. Remineralized evaluation of nano-hydroxyapatite to artificial caries
Júnior et al. Improving Antimicrobial Activity of Dental Restorative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150128